Q2 = 97.5, p < 0-0005); erythrocyte autoantibodies and carcinoma were found together 12-13 times more often than expected from their relative frequencies. Autoantibodies occurred with a variety of carcinomas, particularly those of breast, lung, colon, rectum, and prostate; this largely reflected tumour incidence. Adenocarcinoma, squamous, anaplastic, and transitional cell types were all represented. Warm, cold, and mixed autoantibodies were not associated with particular tumour sites or histology. Eighty six patients had haemolysis of varying severity, 37 had metastatic disease, and 28 died within a few months of presentation. Conclusions-The presence of erythrocyte autoantibodies and carcinoma in the same patient is a true association and probably reflects a fimdamental disturbance in immune homeostasis. It tends to occur with a large tumour mass and metastatic disease, and generally indicates a poor prognosis. Correspondence to: Dr R J Sokol Accepted for publication 27 October 1993 Studies of patients with autoimmune haemolysis, over a period of some 28 years, showed that 5-6% of cases also had non-ovarian carcinomas. ' 2 In a review of 300 people with bronchogenic carcinoma seen over 10 years, two had concomitant autoimmune haemolytic anaemia,3 but in another series of 280 consecutive patients with lung cancer no cases of autoimmune haemolytic anaemia were found. 4 The presence of both autoimmune haemolysis and carcinoma in the same subject is therefore uncommon and the question arises as to whether it is a true association,2 and the development of the two conditions is related, or whether it is a chance event. The Trent Regional Blood Transfusion Centre is in a unique position to study a comparatively large series of such cases as it provides a serological reference service for roughly 4-7 million people living in an area of about 16 800 km2.1 We describe in the present study those patients with both erythrocyte autoantibodies and carcinoma who have been referred to us since 1982; the number was sufficiently large for the validity of the association to be examined statistically.
Methods
A review was carried out of all cases seen in the immunohaematology department between 1 January 1982 and 30 September 1992. The records of patients with erythrocyte autoantibodies and a confirmed diagnosis of carcinoma were selected and critically examined. In all instances samples had been sent because of suspected autoimmune haemolytic anaemia or because autoantibodies were causing considerable difficulties in blood grouping or cross-matching; where cold agglutinins were implicated, they were strongly reactive at 18°C or above. Careful note was made of the site of the primary tumour, the immunohaematological profile, whether there were any other factors which could have predisposed towards the development of autoantibodies, and whether there was clinically important haemolysis. The latter was ascertained from the clinical and laboratory findings, including haemoglobin concentration and its rate of fall, reticulocyte count, blood and marrow film appearances and measurements of red cell lifespan, serum haptoglobins, bilirubin concentration and lactic dehydrogenase activity. The investigations carried out at this centre included direct antiglobulin tests using agglutination and enzyme linked methods and examination of red cell autoantibodies in serum and eluates; full details have been reported elsewhere.' 5 To determine whether erythrocyte auto- 
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Breast and colon years). The analysis of the data in table 1 showed that there was a very highly significant association between erythrocyte autoantibodies and carcinoma (x2 = 97.5; p < 0 0005). Table 2 groups the patients according to the site of the primary tumour and gives details of the sex and age distribution. Full histological data were absent in many cases, but 18 subjects were known to have adenocarcinoma, 10 had squamous cell carcinoma, five had poorly differentiated/anaplastic carcinoma, and five had transitional cell carcinoma; similarly, 37 patients were known to have metastatic disease and 28 died within a few months of presentation.
The serological characteristics of the erythrocyte autoantibodies are shown in table 3, together with the number of patients with evidence of immune mediated haemolysis. The serum haptoglobin concentrations ranged from <0-1 g/l to 5-5 g/l; of the 86 patients deemed to have haemolysis, haptoglobins were reduced (<0.4 g/l) in 21, normal (0 4-1 9 g/l) in 45, and raised ( 2-0 g/l) in 20 . (table 4) had been included, then the figure would be even higher. The data in table 1 are based on certain assumptions as most people "without erythrocyte autoantibodies" were healthy and had not been formally tested. It is felt, however, that the conclusion remains valid as the association would still be significant even if the number of healthy subjects with autoantibodies was six times the 258 quoted. Such an increase would equate with an autoantibody incidence in the general population of about 1 in 3000, which is far higher than in our blood donor or hospital populations. Reports from other institutions suggest that about 1 in 14 000 normal people has a positive direct antiglobulin test7; the comparable figure for this centre is 1 in 13 600. The large number of patients in the present study allowed the controversy over whether there is a true association between carcinoma and autoantibody formations to be resolved statistically. To the best of our knowledge, this is the most extensive series reported. Previously, evidence for an association had come from single case studies8-29 or from those containing only very few patients. 10 It has been suggested that there is a particularly strong association with adenocarcinomas because these tumours secrete mucin-like substances which might have a specific role in inducing autoantibody formation.'4 Tumour histology was available in only a few of the present cases; nevertheless, numbers were sufficient to show that although autoantibodies were frequently associated with adenocarcinoma, the range of histological types was wide. It should also be remembered that adenocarcinoma is a common type of tumour. These observations are in keeping with previous studies, where although autoimmune haemolytic anaemia was associated with adenocarcinoma 39*315 1920273233 tumours of squamous cell,3 1824 30 32 33 undifferentiated/ anaplastic,12 16 21 30 renal clear cell,'7 26 3' transitional cell,29 and oat cell25 31 32 types were also well represented.
Eighty six (54%) patients had evidence of haemolysis (table 3) , although confirmation was often difficult because of the effects of haemorrhage, treatment, and blood transfusions. Anaemia also frequently has multiple causes in patients with carcinoma9 and an autoimmune component may not be a particular problem in the overall clinical context. Serum haptoglobin measurements are less helpful in these circumstances as they are often increased in malignancy,'39 and in several of the present patients with obvious haemolysis, normal or raised concentrations were found. The absence of haemolysis in many cases (table 3) is not surprising in view of our previous observation that overt red cell destruction is only an extreme manifestation of autoantibody formation.2 The publication of so many individual case studies has biased the established findings in favour of patients with active haemolysis, and only a few reports'940 have recognised the association of erythrocyte autoantibodies and carcinoma without increased red cell destruction.
The tumour was known to have spread in 37 of our patients, suggesting that erythrocyte autoantibodies tended to occur where there was a large tumour mass and metastatic disease. As would be expected, these findings indicated a poor prognosis and 28 patients died within a few months of presentation. Data were incomplete and the true figures were almost certainly much higher. Similar observations regarding the association with metastatic disease3 813 16-23 25 27-29 31-33 and short survival 3 9 11-14 16 20 22 23 27 31-33 could also be concluded from previous reports. However, in a few patients with2' or without metastases,32 appropriate treatment resulted in cessation of haemolysis and long survival.
All serological types of autoantibody were found (table 3 ) and the ratio of warm: cold:mixed types (7:3:1) was similar to the 9:4:1 found, overall, in a large series of patients with autoimmune haemolysis.2
The patient groups were too small to determine whether the different serological types were associated with any particular carcinoma. Details of autoantibody type were not always given in previous publications, but warm'6 18 22-24 27 32 and cold17 21 4) ; in the former case, however,24 the biphasic haemolysins had anti-I specificity and were of IgM class.
Possible causes for the autoantibody development, other than carcinoma, were recognised in 35 patients (table 4) . We were initially surprised that a-methyl dopa treatment was the most common (found in 15 cases), rather than lymphoid neoplasia as noted previously.3" However, most of our patients were elderly (mean age 67-8 years) and belonged to a generation in which a-methyl dopa, a potent inducer of red cell autoantibodies, was widely prescribed.
Several proposals for the mechanism of autoantibody production in patients with carcinoma have been made: (i) the tumour modifies red cell antigens so that an autoantibody response is elicited'5'9 20; (ii) the autoantibodies are formed against tumour antigens and cross-react with the erythrocytes"5202228 29;
(iii) the carcinoma produces the red cell autoantibodies'5 20 22 28; (iv) immune complexes, formed between tumour associated antigens and antibodies, bind to the red cells and cause haemolysis through the action of complement20 22; (v) immune dysfunction in patients with carcinoma results in forbidden clones of lymphocytes frequently escaping surveillance, but these are only recognised when they have clinical consequences such as autoimmune haemolysis'63; and (vi) there is a failure of immune homeostasis which permits both tumour growth and autoantibody production. The different theories are not mutually exclusive and, no doubt, more than one may be operative in a particular patient. We have long regarded erythrocyte autoantibody formation and autoimmune haemolysis as reflecting a fundamental disturbance in immune homeostasis,' and it is of interest that carcinoma developed in three of our patients with autoimmune haemolytic anaemia (table 4); a similar occurrence was noted in tWO20 31 out of 34 others39 "-33 where these conditions were associated.
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